Neurogene (NGNE) said Monday it likely will not move forward with its NGN-101 CLN5 Batten disease gene therapy program after the US Food and Drug Administration denied a Regenerative Medicine Advance Therapy application for the program.
Neurogene shares were falling 35% in recent after-hours trading.
"Given the rarity of the disease, continued investment in the program was predicated on alignment on a streamlined registrational pathway with FDA," the company said, adding the regulator denied the RMAT application.
Neurogene said it's "evaluating options for the program."
Neurogene also said Monday it has seen "positive" interim results in the first four participants in the low-dose group of a phase 1/2 trial assessing NGN-401 gene therapy to treat female pediatric patients with Rett syndrome, a neurodevelopmental disease.
The company said it expects to provide an update of registrational trial design in H1 2025 and will release more interim phase 1/2 results in H2 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.